Biocon is confident of its “four channel strategy” for the upcoming debut of biosimilar Humira in the US and also asserts it’s well positioned to compete when price cuts come into play for Sanofi’s Lantus next year.

Biocon is confident of its “four channel strategy” for the upcoming debut of biosimilar Humira in the US and also asserts it’s well positioned to compete when price cuts come into play for Sanofi’s Lantus next year.

Ahead of joining a second wave of Humira biosimilars hitting the US market in just a couple of months, Organon has projected a “modest ramp” in initial sales for its Hadlima version in 2023.

Newfoundland and Labrador has become the ninth jurisdiction in Canada to implement a biosimilar switching policy for patients enrolled on its public health program.